Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.

Lancet. 2013 Mar 9;381(9869):805-16. Erratum in: Lancet. 2013 Mar 9;381(9869):804.

2.

New arguments to explain the high infection rate in posttraumatic spleenless patients.

el Akkad H, Sass W, Colberg A, Knippert A, Seifert J.

Zentralbl Chir. 1997;122(10):909-13.

PMID:
9401117
3.

The value of combination chemotherapy and radiotherapy in the management of primary non-small-cell lung carcinoma in Alexandria.

Moussa-Mahmoud I, Ramadan A, Abdou L, Fouad A, el-Akkad H.

Chemioterapia. 1987 Jun;6(2 Suppl):704-6. No abstract available.

PMID:
2855623

Supplemental Content

Loading ...
Support Center